| Primary information |
|---|
| sequence ID | Seq_7691 |
| Peptide sequence | SSRQLGLPGPPDVPDHAAYHPF |
| CancerPDF_ID | CancerPDF_ID52, CancerPDF_ID775, CancerPDF_ID1063, CancerPDF_ID8567, CancerPDF_ID9939, CancerPDF_ID9947, |
| PMID | 16896061,19795908,16395409,23667664,21124649,21137033 |
| Protein Name | Inter-alpha-trypsin inhibitor heavy chain H10,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H8,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4 |
| UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Serum |
| M/Z | 2358.09,786.72,2358.09,2357.16,NA,NA |
| Charge | 1,3,1,1,NA,NA |
| Mass (in Da) | 2358.15,NA,NA,2359.61,NA,NA |
| fdr | NA,NA,NA,NA,2358.6,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,FT-ICR MS/MS + nano-HPLC,LC-ESI-MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Labelled,Labelled |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,NA |
| CancerPDF_ID | CancerPDF_ID52, CancerPDF_ID775, CancerPDF_ID1063, CancerPDF_ID8567, CancerPDF_ID9939, CancerPDF_ID9947, |
| p-Value | 1.00E-05,NA,8.65E-13,NA,4.07E-12,less than 0.05 |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT,NA,NA |
| Length | 22,22,22,22,22,22 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer","Breast cancer, Lung cancer, Rectal cancer",Breast cancer,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,NA,NCBI Protein Database,NA |
| Modification | NA,NA,NA,NA,ITIH4-22,ITIH4-22 |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",9 BC and 9 control,45 BC and 78 control |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =100, 73 and 531 in prostate, bladder and breast cancer respectively",NA,Differentially expressed between cancer vs control,Differentially expressed between cancer vs control |
| Validation | Independent validation,NA,Independent validation,NA,NA,NA |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |